The deal also allows Sanofi to use Novavax's Covid shot and flagship vaccine technology, Matrix-M adjuvant, to develop new ...

This decision follows the positive opinion from the Committee for Medicinal Products fo Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna ...

Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89 ...

Finally, it also includes a non-exclusive license to use the Matrix-M adjuvant in vaccine products. On top of all of this, Sanofi is taking a minority stake in Novavax. That will see it hold less ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Novavax shares ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other under-the-radar stocks. Investing in under-the-radar stocks can be a savvy move for those ...

In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) crossed above their 200 day moving average of $10.66, changing hands as high as $11.55 per share. Novavax, Inc. shares are currently ...

In the latest trading session, Novavax (NVAX) closed at $8.55, marking a +0.53% move from the previous day. The first human bird flu death in the US has Moderna's vaccine development in focus for ...